Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.
Robert Califf has scheduled the end of his time as FDA commissioner and it appears a familiar face might temporarily take his place.
Stephen Ostroff, deputy commissioner for foods and veterinary medicine, appears in line to become the acting commissioner, assuming Califf departs...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
